Immune response modulator (IRM)

An immune response modulator (also known as an immunomodulator) is a functional class of substances that regulate the activity of the immune system to achieve a therapeutic effect [1, 13]. These agents do not represent a single biological target but instead include a wide variety of specific receptors, enzymes, and signaling proteins, such as Toll-like receptors (TLRs), cytokines, and immune checkpoint molecules like PD-1 or CTLA-4 [1, 2, 11]. Immunomodulators are categorized as either stimulants, which enhance the immune response to combat cancer or infections, or suppressants, which dampen the immune response to treat autoimmune diseases or prevent organ transplant rejection [12, 16]. Examples of specific targets within this category include TLR7/8 for imidazoquinoline drugs, or the E3 ubiquitin ligase cereblon for immunomodulatory imide drugs (IMiDs) [11, 13, 1]. Because the term describes a broad physiological role or pharmacological class rather than a specific molecular entity, it is not considered a distinct therapeutic target in drug discovery [2, 3]. Clinical application of these modulators requires precise monitoring of specific immune pathways to avoid systemic complications like cytokine storms or severe autoimmunity [16].

Other names

ImmunomodulatorImmune response modifierBiological response modifierBRM

Immune response modulators function via multiple distinct molecular mechanisms, including the activation of pattern recognition receptors (e.g., TLR7/8), the blockade of inhibitory immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), the modulation of cytokine signaling through direct administration or receptor antagonism, and the induction of targeted protein degradation via E3 ubiquitin ligase recruitment.